Floatz logo

Polatuzumab Vedotin

Burkitt Lymphoma

New York Medical Collegeantibody_drug_conjugatePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

73 Active assets in the Burkitt Lymphoma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 4BBB
VINCRISTINE SULFATE
AIDS Malignancy Consortium
Phase 2BBB
VINDESINE
PETHEMA Foundation
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
AIDS Malignancy Consortium
Phase 4BBB

View all 50 →

Same molecule, other indications

Polatuzumab Vedotin is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Refractory Diffuse Large B-Cell LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Large B-Cell Lymphoma (LBCL)Dormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →